Action CGEM CULLINAN THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues Cullinan Therapeutics, Inc.

Actions

CGEM

US2300311063

Marché Fermé - Nasdaq
Autres places de cotation
 22:00:00 28/05/2024 		Varia. 5j. Varia. 1 janv.
23,03 USD -4,56 % Graphique intraday de Cullinan Therapeutics, Inc. -0,56 % +126,01 %
15/05 Cullinan Therapeutics, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024 CI
15/05 Cullinan Therapeutics, Inc. annonce des changements au sein de son conseil d'administration CI

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Cullinan Therapeutics to Participate in Fireside Chat at TD Cowen 5th Annual Oncology Innovation Summit
Cullinan Therapeutics to Present First Data for CLN-619, a Novel Anti-MICA/B Antibody, in Combination with a Checkpoint Inhibitor and Updated Monotherapy Data at ASCO 2024
Cullinan Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
Cullinan Therapeutics, Inc. Announces Board Changes
Cullinan Therapeutics Insider Sold Shares Worth $1,796,676, According to a Recent SEC Filing
Cullinan Therapeutics Appoints Mary Kay Fenton as CFO
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics Announces Appointment of Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics, Inc Appoints Mary Kay Fenton as Chief Financial Officer
Cullinan Therapeutics to Present Clinical Data from Phase 1 Study Evaluating Novel Anti-MICA/B Antibody, CLN-619, as Monotherapy and in Combination with a Checkpoint Inhibitor in Patients with Advanced Solid Tumors at ASCO 2024
Cullinan Oncology : Therapeutics Corporate Update
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Therapeutics Announces Strategic Expansion into Autoimmune Diseases
Cullinan Oncology, Inc. Announces Important Updates About Its Plan to Expand into Autoimmune Diseases, the Scientific Rationale for Developing CLN-978 in Autoimmune Diseases
Cullinan Therapeutics Announces Oversubscribed $280 million Private Placement
Cullinan Oncology, Inc. announced that it expects to receive $280.000024 million in funding from a group of investors
Cullinan Oncology, Inc.(NasdaqGS:CGEM) added to S&P Biotechnology Select Industry Index
Cullinan Oncology Finance Chief Jeffrey Trigilio to Leave
Cullinan Oncology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action CGEM
  4. Actualités Cullinan Therapeutics, Inc.
  5. Autres langues
-40% Offre à Durée Limitée : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT